Rs11479 in Thymidine Phosphorylase Associated with Prognosis of Patients with Colorectal Cancer Who Received Capecitabine-Based Adjuvant Chemotherapy
DOI: https://doi.org/10.2147/PGPM.S397382
2023-04-01
Pharmacogenomics and Personalized Medicine
Abstract:Xiongjie Jia, &ast Tao Zhang, &ast Junjie Sun, Hengxue Lin, Tianliang Bai, Yating Qiao, Yaxin Li, Gang Li, Guicun Li, Xinyu Peng, Aimin Zhang Department of Gastrointestinal Surgery, Affiliated Hospital of Hebei University, Baoding, People's Republic of China &astThese authors contributed equally to this work Correspondence: Aimin Zhang; Xinyu Peng, Department of Gastrointestinal Surgery, Affiliated Hospital of Hebei University, No. 212 Yu-Hua East Road, Baoding City, Hebei Province, People's Republic of China, Tel +863125983782, Email ; Objective: Thymidine Phosphorylase (TYMP) gene was of potential significance in the process of colorectal cancer (CRC) development and played an important role in capecitabine metabolism. This study was to identify the association between TYMP polymorphism and prognosis of postoperative patients with CRC who received capecitabine-based adjuvant chemotherapy. Methods: A total of 218 patients with CRC who were treated with surgical resection and capecitabine-based adjuvant chemotherapy were included in this study retrospectively. Peripheral blood and peripheral blood mononuclear cell (PBMC) specimen of the patients were collected for the genotyping of TYMP polymorphism and TYMP mRNA expression, respectively. Univariate analysis of genotypes and prognosis was carried out by Kaplan–Meier survival analysis, Cox regression analysis was adopted in multivariate analysis. The mRNA expression of TYMP according to genotype status was analyzed using non-parameter test. Results: Prevalence of rs11479 in TYMP among the 218 patients exhibited that minor allele frequency of rs11479 was 0.20 (GG 141 cases, GA 68 cases and AA 9 cases), which was in accordance with Hardy-Weinberg equilibrium ( P =0.825). Association analysis suggested that the median disease-free survival (DFS) of patients with GG genotype and GA/AA genotype was 3.1 and 6.1 years, respectively ( P =0.004). Furthermore, the median overall survival of patients with GG genotype and GA/AA genotype was 5.0 and 7.0 years, respectively ( P =0.033). Multivariate Cox regression analysis exhibited that rs11479 polymorphism was an independent factor for DFS (HR = 1.64, P =0.009). Additionally, of the 65 PBMC specimens, mRNA expression results indicated that patients with GA/AA genotypes conferred significantly higher mRNA expression of TYMP than that of patients with GG genotype ( P < 0.001). Conclusion: Polymorphism rs11479 in TYMP gene might predict the prognosis of patients with CRC who received capecitabine-based adjuvant chemotherapy through mediation of the mRNA expression of TYMP . The conclusion of this study should be validated in prospective clinical trials subsequently. Keywords: colorectal cancer, adjuvant chemotherapy, capecitabine, prognosis, polymorphism Colorectal cancer (CRC) is one of the most common gastrointestinal tumors worldwide. It is estimated that there are approximately 56,000 new cases and 29,000 new deaths of CRC in China currently. 1 To our knowledge, surgical resection was established to be curable for patients with CRC over the past decades. Unfortunately, approximately 30% of the patients were diagnosed of distant metastasis, thus missing the opportunity for surgical resection. 2 Consequently, almost half of the patients with CRC were able to receive surgical resection clinically. Recent years had witnessed in-depth progress of molecular status in colon cancer or rectal cancer with advanced stage, more and more targeted drugs with different targets of action were developed to provide considerable treatment options, thus bringing survival benefits for the patients consecutively. 3 Nevertheless, meaningful research progress in early-stage and postoperative patients with CRC was still limited comparatively. It was known that IDEA trial was proved to be the significant breakthrough with clinical significance recently, which suggested that 3 months rather than 6 months of adjuvant chemotherapy was recommended for low-risk stage III colon cancer to receive 5-FU related regimens. 4 Conclusions of IDEA trial helped to attenuate the unnecessary side reactions of chemotherapy to some extent in view of the fact that 6 months adjuvant chemotherapy regimens were established to be the standard of care for stage III patients with CRC for decades. 5 The IDEA trial also highlighted more work should be performed to refine the adjuvant chemotherapy for patients with CRC, which was in line with the aim of our study. Besides, with the adequate development of the more sensitive detection techniques, ctDNA had established to be the pot -Abstract Truncated-
pharmacology & pharmacy